Attenuation of the development of morphine dependence/tolerance by nefiracetam: Involvement of adenosine 3':5'-cyclic monophosphate system

Behavioural Brain Research

Volumn 115, Issue 1, 2000, Pages 65-74

  Itoh, Akio ^a   Shiotani, Tadashi ^a   Nakayama, Shinobu ^a   Mamiya, Takayoshi ^a   Hasegawa, Takaaki ^a   Noda, Yukihiro ^a   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

cAMP; Dependence and tolerance; Morphine; Phosphodiesterase; Withdrawal symptom

Indexed keywords

CALCIUM; CYCLIC AMP; ENPROFYLLINE; MORPHINE; NALOXONE; NEFIRACETAM; THEOPHYLLINE;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BRAIN CORTEX; BRAIN LEVEL; CONTROLLED STUDY; MALE; MORPHINE ADDICTION; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ANIMAL; BRAIN CHEMISTRY; CEREBRAL CORTEX; CYCLIC AMP; DRUG TOLERANCE; MALE; MICE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; PHOSPHODIESTERASE INHIBITORS; PSYCHOTROPIC DRUGS; PYRROLIDINONES; SUBSTANCE WITHDRAWAL SYNDROME; SUPPORT, NON-U.S. GOV'T; THEOPHYLLINE; XANTHINES;

EID: 0033833836     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(00)00237-0     Document Type: Article

References (38)

1. Birnbaumer L. G proteins in signal transduction. Ann Rev Pharmacol Toxicol. 30:1990;675-705.
2. Butcher R.W., Sutherland E.W. Adenosine 3′,5′-phosphate in biological materials. J Biol Chem. 237:1962;1244-1250.
3. Chapman D.B., Way E.L. Modification of endorphin/enkephalin analgesia and stress-induced analgesia by divalent cations, a cation chelator and an ionophore. Br J Pharmacol. 75:1982;389-396.
4. Collier H.O. Cellular site of opiate dependence. Nature. 283:1980;625-629.
5. Copeland R.J. Jr., Pradhan S.N., Dillon-Carter O., Chuang D.M. Rebound increase of basal cAMP level in NG108-15 cells during chronic morphine treatment: effects of naloxone and chloramphenicol. Life Sci. 44:1989;1107-1116.
6. Dary L.W. Adenosine receptors: Targets for future drugs. J Med Chem. 25:1982;197-207.
7. Duman R.S., Tallman J.F., Nestler E.J. Acute and chronic opiate-regulation of adenylate cyclase in brain: Specific effects in locus coeruleus. J Pharmacol Exp Ther. 246:1988;1033-1039.
8. Fedulova S.A., Kostyok P.J., Veselovsky N.S. Calcium channels in somatic membrane of the rat dorsal root ganglion neurons, effect of cAMP. Brain Res. 214:1981;210-214.
9. Geary W.A., Wooten G.F. Dose effects of naloxone on fixed morphine dependence: simultaneous behavioral and 2-deoxyglucose study in the rat. Brain Res. 332:1985;69-78.
10. ++ uptake. J Pharmacol Exp Ther. 209:1979;132-136.
11. Guiart X., Thompson M.A., Mirante C.K., Greenberg M.E., Nestler E.J. Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the rat locus coeruleus. J Neurochem. 58:1992;1168-1171.
12. Haghgoo S., Hasegawa T., Nadai M., Wang L., Ishigaki T., Miyamoto K., Nabeshima T. Brain distribution characteristics of xanthine derivatives and relation to their locomotor activity in mice. J Pharm Pharmacol. 47:1995;412-419.
13. Harris R.A., Yamamoto H., Loh H.H., Way E.L. Discrete changes in brain calcium with morphine analgesia, tolerance-dependence, and abstinence. Life Sci. 20:1977;501-506.
14. Hasegawa T., Miyamoto K., Wakusawa S., Takagi K., Apichartpichean R., Kuzuya T., Nadai M., Horiuchi T. Relationship between hydrophobicity and biological activities of xanthine derivatives in guinea pig tracheal smooth muscle. Int J Pharm. 58:1990;129-134.
15. Karlsten R., Post C., Hide I., Daly J.W. The antinociceptive effect of intrathecally administered adenosine analogs in mice correlates with the affinity for the A1-adenosine receptor. Neurosci Lett. 121:1991;267-270.
16. Korf J., Bunney B.S., Aghajanian G.K. Noradrenergic neurons: morphine inhibition of spontaneous activity. Eur J Pharmacol. 25:1974;165-169.
17. Lane-Ladd S.B., Pineba J., Boundy V.A., Pfeuffer T., Krupinski J., Aghajanian G.K., Nestler E.J. CREB (cAMP response element-binding protein) in the locus coeruleus: biochemical, physiological, and behavioral evidence for a role in opiate dependence. J Neurosci. 15:1997;7890-7901.
18. Maldonado R., Blendy J.A., Tzavara E., Gass P., Roques B.P., Hanoune J. Reduction of morphine abstinence in mice with a mutation in the gene encoding CREB. Science. 273:1996;657-659.
19. Mantegazza P., Tammiso R., Zambotti F., Zecca L., Zonta N. Purine involvement in morphine antinociception. Br J Pharmacol. 83:1984;883-888.
20. Montminy M.R., Gonzalez G.A., Yamamoto K.K. Regulation of cAMP-inducible genes by CREB. Trends Neurosci. 13:1990;184-188.
21. Murashima Y.L., Shinozaki T., Watabe S., Yoshii M. DM-9384, a cyclic GABA derivative, elevates the c-AMP level in NG 108-15 cell. Neurosci Res (Suppl). 16:1991;S61.
22. Nabeshima T. Ameliorating effects of nefiracetam (DM-9384) on brain dysfunction. Drugs Today. 30:1994;357-379.
23. Nabeshima T., Nakayama S., Ichihara K., Yamada K., Shiotani T., Hasegawa T. Effects of nefiracetam on drug-induced impairment of latent learning in mice in a water finding task. Eur J Pharmacol. 255:1994;57-65.
24. Nabeshima T, Noda Y, Mamiya T. Prevention of development of dependence to morphine by using cyclic AMP-related compounds in mice. In: Okada Y, editors, The Role of Adenosine in the Nervous System. Amsterdam: Elsevier Science B.V., 1997.
25. Nestler E.J. Adaptive changes in signal transduction systems: molecular mechanisms of opiate addiction in the rat locus coeruleus. Prog Cell Res. 1:1990;73-88.
26. Nestler E.J. Under siege: The brain on opiates. Neuron. 11:1996;995-1006.
27. Nestler E.J., Hope B.T., Widnell K.L. Drug addiction: a model for the molecular basis of neural plasticity. Neuron. 11:1993;995-1006.
28. Persson C.G.A., Anderson K.E., Kjellin G. Effects of enprofylline and theophylline may show the role of adenosine. Life Sci. 38:1986;1057-1072.
29. Ramkumar V., El-Fakahany E.E. Prolonged morphine treatment increases rat brain dihydropyridine binding sites: possible involvement in development of morphine dependence. Eur J Pharmacol. 146:1988;73-83.
30. Rasmussen H., Barrett P.Q. Calcium messenger system: an integrated view. Physiol Rev. 64:1984;938-984.
31. Sharma S.K., Nirenberg M., Klee W.A. Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci USA. 72:1975;590-594.
32. 2+-regulated transcriptional factor phosphorylated by calmoduline-dependent kinases. Science. 252:1991;1427-1430.
33. Terwilliger R.Z., Johnson D.B., Sevarino K.A., Crain S.M., Nestler E.J. A general role for adaptations in G-proteins and cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res. 548:1990;100-110.
34. Watabe S., Yamaguchi H., Ashida S. DM-9384, a new cognition-enhancing agent, increases the turnover of components of the GABAergic system in the rat cerebral cortex. Eur J Pharmacol. 238:1993;303-309.
35. Yamamoto H., Harris R.A., Loh H.H., Way E.L. Effects of acute and chronic morphine treatments on calcium localization and binding in brain. J Pharmacol Exp Ther. 205:1978;255-264.
36. Yamada K., Nakayama S., Shiotani T., Hasegawa T., Nabeshima T. Possible involvement of the activation of voltage-sensitive calcium channels in the ameliorating effects of nefiracetam on scopolamine-induced impairment of performance in a passive avoidance task. J Pharmacol Exp Ther. 270:1994;881-892.
37. Yamada K., Nabeshima T. Nefiracetam (DM-9384): a novel antiamnesic drug. CNS Drugs Rev. 2:1996;322-342.
38. Yoshii M., Watabe S. Enhancement of neuronal calcium channel currents by the nootropics on high-voltage activated calcium channels in NG108-15 cells. Brain Res. 642:1994;123-131.